论文部分内容阅读
1998年5月16～19日在洛杉矶召开了美国临床肿瘤学会第34届年会。现将本届大会有关血液系统肿瘤临床研究的报道重点介绍如下。1 急性髓系白血病(AML)1.1 老年AML:Gottingen大学的Hiddemann等报告,德国AML患者年龄中位数为65岁;老年AML(>60岁)在形态学上易有一系或多系细胞增生不良,且往往具有不利的生物学预后因素,如复杂的染色体核型异常、mdr-1高表达等,提示白血病病变发生于较早期的多能干细胞。治疗上,与姑息治疗相比,老年AML患者接受常规化疗,平均生存期由11周延长至21周,2
The 34th annual meeting of the American Society of Clinical Oncology was held in Los Angeles from May 16 to May 19, 1998. The current report of the General Assembly on the clinical research of hematological tumors is highlighted below. 1 Acute Myeloid Leukemia (AML) 1.1 Aged AML: Hiddemann et al. of Gottingen University reported that the median age of AML patients in Germany is 65 years old; older AML (>60 years old) is morphologically susceptible to one or more lines of dysplasia , And often have unfavorable biological prognostic factors, such as complex karyotypic abnormalities, mdr-1 high expression, etc., suggesting that leukemia lesions occurred in earlier pluripotent stem cells. Treatment, compared with palliative care, elderly AML patients received conventional chemotherapy, the average survival time from 11 weeks to 21 weeks, 2